The impact of COVID-19 on cancer care of outpatients with low socioeconomic status.


Journal

International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124

Informations de publication

Date de publication:
01 07 2022
Historique:
revised: 22 01 2022
received: 02 12 2021
accepted: 27 01 2022
pubmed: 8 2 2022
medline: 18 5 2022
entrez: 7 2 2022
Statut: ppublish

Résumé

Patients with low socioeconomic status (SES) are among the most underserved groups of people regarding cancer care. Analyzing the impact of the coronavirus-induced disease 2019 (COVID-19) pandemic on health care disparities and calling attention to inequalities in cancer care is crucial to justify and initiate adequate countermeasures. We aimed to determine whether the COVID-19 pandemic aggravated health care disparities of cancer outpatients related to their SES and analyzed patient data of the largest university center providing services for patients with hematologic and oncologic disorders in Austria from 2018 to 2021. SES was assessed using three indicators: monthly net household income, level of education and occupational prestige. In total, 1217 cancer outpatients (51.1% female) with a mean age of 59.4 years (SD = 14.2) participated. In the first year of the pandemic, the relative proportion of individuals with low income, low education level and low occupational prestige seeking cancer care at our outpatient center decreased significantly (P ≤ .015). The strongest indicator was income, with a consistent effect throughout the first pandemic year. Countermeasures and specific interventions to support cancer patients with low SES in their access to health care should be initiated and prioritized.

Identifiants

pubmed: 35128650
doi: 10.1002/ijc.33960
pmc: PMC9087749
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

77-82

Informations de copyright

© 2022 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.

Références

Epidemiol Rev. 2011;33:135-47
pubmed: 21586673
Perspect Public Health. 2021 May;141(3):158-176
pubmed: 32449467
JAMA Otolaryngol Head Neck Surg. 2021 Feb 1;147(2):209-211
pubmed: 33151289
JCO Glob Oncol. 2020 Jun;6:906-912
pubmed: 32589462
Oncologist. 2021 Feb;26(2):e338-e341
pubmed: 33111460
Cancer Med. 2021 Dec;10(24):8854-8865
pubmed: 34845860
J Surg Oncol. 2020 Sep;122(3):371-372
pubmed: 32452031
JAMA Oncol. 2020 Oct 1;6(10):1531-1532
pubmed: 32789508
JAMA Netw Open. 2021 May 3;4(5):e2110946
pubmed: 34028552
J Epidemiol Community Health. 2001 Oct;55(10):693-700
pubmed: 11553651
Int J Cancer. 2022 Jul 1;151(1):77-82
pubmed: 35128650
Int J Cancer. 2022 Apr 15;150(8):1244-1254
pubmed: 34843106
Health Expect. 2022 Apr;25(2):506-512
pubmed: 33974721
Lancet Oncol. 2020 Aug;21(8):1023-1034
pubmed: 32702310

Auteurs

Elisabeth L Zeilinger (EL)

Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.

Simone Lubowitzki (S)

Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.

Matthias Unseld (M)

Division of Palliative Medicine, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.

Carmen Schneckenreiter (C)

Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.

Daniel Heindl (D)

Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.

Philipp B Staber (PB)

Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.

Markus Raderer (M)

Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.

Peter Valent (P)

Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Ludwig Boltzmann Institute for Hematology and Oncology, Vienna, Austria.

Sabine Zöchbauer-Müller (S)

Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.

Rupert Bartsch (R)

Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.

Gerald Prager (G)

Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.

Ulrich Jaeger (U)

Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.

Alexander Gaiger (A)

Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH